Loading organizations...
§ Private Profile · South San Francisco, CA, USA
biotechnology company focused on drug discovery and development for acute cardiovascular diseases, applying PKC biology to create.
Key people at KAI Pharmaceuticals.
KAI Pharmaceuticals, a biotechnology company based in South San Francisco, California, specializes in drug discovery and development for acute cardiovascular and other diseases with unmet medical needs, applying expertise in protein kinase C (PKC) biology to create selective inhibitors and activators. The company secured $35 million in Series B financing in 2006 and entered a collaboration and license agreement with Daiichi-Sankyo in 2005, valued at up to $340 million for the development of KAI-9803. Lead investors included Investor Growth Capital, Aberdare Ventures, Skyline Ventures, and InterWest Partners, with board members such as Curt H. LaBelle and Daniel L. Kisner. KAI Pharmaceuticals was subsequently acquired by Amgen in 2012, integrating its drug pipeline and research capabilities. It was founded in 2002 by Daria Mochly-Rosen.
Key people at KAI Pharmaceuticals.
KAI Pharmaceuticals was a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, specializing in treatments for cardiovascular and kidney diseases.[2][4] It developed peptide-based therapies, including its lead candidate etelcalcetide (KAI-4169), a calcimimetic for chronic kidney disease-mineral bone disorder (CKD-MBD) and secondary hyperparathyroidism, which reached approval in the European Union in November 2016.[1][5] The company addressed unmet needs in renal and cardiovascular conditions through mechanisms like CaSR agonists, with a pipeline including delcasertib for infarction and others in pending phases; it served patients with hyperparathyroidism, spinal cord injuries, and perioperative ischemia.[1] KAI operated with around 15 employees until its acquisition by Amgen in 2012, marking the end of its independent growth.[3][4]
KAI Pharmaceuticals emerged as a biotech focused on innovative peptide drugs for serious diseases, though specific founding year and founders are not detailed in available records.[1][2] Its early traction centered on advancing KAI-4169 into clinical trials starting around 2011-2012, targeting CKD-MBD, alongside other candidates like KAI-1678 for spinal cord injuries.[1][5] A pivotal moment came in July 2012 when Amgen acquired the privately held company, integrating its pipeline—particularly the promising etelcalcetide—into Amgen's broader renal portfolio.[3][5] This acquisition highlighted KAI's rapid progress from development to strategic value in under a decade of operation.[2]
KAI stood out in the biopharma space through its specialized pipeline and technology:
KAI rode the early 2010s wave of peptide therapeutics and calcimimetics in nephrology, addressing rising chronic kidney disease burdens amid aging populations and dialysis growth.[1][5] Timing was ideal post-2000s biotech boom, when renal drugs like etelcalcetide filled voids left by first-generation therapies, influencing Amgen's dominance in CKD-MBD markets.[3] Market forces like increasing end-stage renal disease prevalence (driven by diabetes and hypertension) favored its pipeline, while its acquisition exemplified how small biotechs fuel big pharma innovation—transferring 8 patents, trials, and literature to amplify ecosystem impact in cardiovascular-renal therapies.[1][2]
Post-2012 acquisition, KAI's legacy endures through etelcalcetide, now commercialized by Amgen as Parsabiv for secondary hyperparathyroidism, with ongoing global approvals and use in dialysis patients.[1][3] Next steps involve Amgen expanding its applications amid trends like precision nephrology and combo therapies for CKD. Evolving biosimilars and AI-driven drug design could challenge it, but KAI's foundational peptides position Amgen to shape renal care, underscoring how nimble biotechs like KAI accelerate breakthroughs in high-need diseases.[1][5]
